International Clinical Trial: A study on the efficacy and safety of vunakizumab in the treatment of moderate-to-severe hidradenitis suppurativa

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132681) titled 'A study on the efficacy and safety of vunakizumab in the treatment of moderate-to-severe hidradenitis suppurativa' on Sept. 17.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Condition: Moderate-to-Severe Hidradenitis Suppurativa

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2025-07-16

Target Sample Size: Vunakizumab:42;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=305078

Published by HT Digital Content S...